Financials Cybin Inc.

Equities

CLXPF

CA23256X4075

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:00 2025-06-20 pm EDT			5-day change	1st Jan Change
7.780 ^USD	-1.52%		-10.06%	-11.79%

Jun. 13	Cybin Inc. Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics	CI
Jun. 13	Cybin Provides Corporate Update, Highlights Positive Regulatory Signals For Psychedelic Therapeutics	RE

Projected Income Statement: Cybin Inc.

Fiscal Period: March	2020	2021	2022	2023	2024	2025	2026	2027
Net sales ¹	-	0.864	-	-	-	-	-	9.9
Change	-	-	-	-	-	-	-	-
EBITDA ¹	-	-19.17	-45.64	-46.58	-78.41	-132.8	-105.3	-98.05
Change	-	-	-138.08%	-2.06%	-68.33%	-69.43%	20.74%	6.89%
EBIT ¹	-	-32.28	-63.84	-51.52	-78.84	-128.3	-116.8	-140.9
Change	-	-	-97.76%	19.3%	-53.03%	-62.79%	8.96%	-20.62%
Interest Paid ¹	-	1.696	-3.793	-	0.756	-8.07	-2.5	-2.5
Earnings before Tax (EBT) ¹	-	-32.22	-67.63	-47.49	-78.08	-108.2	-112	-134.3
Change	-	-	-109.9%	29.78%	-64.41%	-38.54%	-3.58%	-19.89%
Net income ¹	-0.8098	-32.22	-67.63	-47.49	-78.08	-110.5	-112.3	-129.5
Change	-	-3,878.51%	-109.9%	29.78%	-64.41%	-41.58%	-1.62%	-15.32%
Announcement Date	11/9/20	6/28/21	6/22/22	6/27/23	6/26/24	-	-	-

¹CAD in Million

Estimates

Fiscal Period: March	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4	2027 Q1	2027 Q2	2027 Q3
Net sales ¹	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA ¹	-11.42	-8.015	-9.128	-11.61	-11.95	-12.95	-11.19	-11.2	-11.04	-13.15	-12.64	-13.84	-26.88	-25.05	-20.18	-58.11	-31.17	-23.4	-23.75	-25.25	-27	-29.35	-	-	-
Change	-	29.81%	-13.89%	-27.16%	-2.99%	-8.34%	13.62%	-0.08%	1.36%	-19.11%	3.92%	-9.5%	-94.25%	6.8%	19.45%	-187.98%	46.36%	24.93%	-1.5%	-6.32%	-6.93%	-8.7%	-	-	-
EBIT ¹	-11.43	-13.82	-13.94	-17.11	-16.46	-16.34	-13.4	-12.33	-12.09	-13.7	-12.71	-13.91	-27.02	-25.2	-20.32	-58.25	-31.3	-26.6	-26.07	-27.31	-28.73	-30.79	-41.96	-44.06	-46.3
Change	-	-20.92%	-0.83%	-22.72%	3.81%	0.71%	18.01%	7.97%	1.9%	-13.31%	7.27%	-9.47%	-94.28%	6.77%	19.36%	-186.73%	46.26%	15.02%	1.99%	-4.76%	-5.2%	-7.17%	-36.25%	-5.01%	-5.08%
Charge d'intérêts ¹	-	-	0.044	0.051	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.25	-1	-0.75	-0.5	-0.25	-1	-0.75	-0.5
Earnings before Tax (EBT) ¹	-11.42	-13.78	-14.72	-17.61	-17.21	-18.1	-13.06	-9.973	-10.74	-13.72	-14.51	-11.89	-30.33	-21.35	-14.82	-57.19	-10.54	-25.63	-25.8	-27.04	-28.53	-30.67	-41.86	-43.96	-46.2
Change	-	-20.66%	-6.82%	-19.64%	2.25%	-5.15%	27.86%	23.61%	-7.71%	-27.72%	-5.79%	18.08%	-155.09%	29.62%	30.55%	-285.81%	81.57%	-143.12%	-0.66%	-4.81%	-5.53%	-7.48%	-36.48%	-5.02%	-5.09%
Net income ¹	-11.42	-13.78	-14.72	-17.61	-17.21	-18.1	-13.06	-10	-10.74	-13.72	-14.51	-11.89	-30.33	-21.35	-14.82	-57.19	-10.54	-26.05	-26.24	-27.28	-28.53	-30.29	-34.93	-36.1	-37.35
Change	-	-20.66%	-6.82%	-19.64%	2.25%	-5.15%	27.86%	23.4%	-7.42%	-27.72%	-5.79%	18.08%	-155.09%	29.62%	30.55%	-285.81%	81.57%	-147.14%	-0.71%	-3.97%	-4.57%	-6.16%	-15.33%	-3.37%	-3.45%
Announcement Date	2/16/21	6/28/21	8/13/21	11/15/21	2/10/22	6/22/22	8/8/22	11/14/22	2/14/23	6/27/23	8/14/23	11/14/23	2/14/24	6/26/24	8/8/24	11/13/24	2/11/25	-	-	-	-	-	-	-	-

¹CAD in Million

Estimates

Forecast Balance Sheet: Cybin Inc.

Fiscal Period: March	2020	2021	2022	2023	2024	2025	2026	2027
Net Debt ¹	-	-64	-53.6	-16.6	-209	-111	-19.5	-344
Change	-	-	16.25%	69.03%	-1,159.04%	46.81%	82.43%	-1,664.1%
Announcement Date	11/9/20	6/28/21	6/22/22	6/27/23	6/26/24	-	-	-

¹CAD in Million

Estimates

Cash Flow Forecast: Cybin Inc.

Fiscal Period: March	2021	2022	2023	2024	2025	2026	2027
CAPEX ¹	0.135	0.105	0.142	0.021	0.4783	4.524	8.363
Change	-	-22.22%	35.24%	-85.21%	2,177.76%	845.86%	84.85%
Free Cash Flow (FCF) ¹	-19.16	-45.31	-47.57	-68.93	-105.4	-103	-103.8
Change	-	-136.47%	-4.99%	-44.89%	-52.91%	2.32%	-0.83%
Announcement Date	6/28/21	6/22/22	6/27/23	6/26/24	-	-	-

¹CAD in Million

Estimates

Forecast Financial Ratios: Cybin Inc.

Fiscal Period: March	2020	2021	2022	2023	2024	2025	2026	2027
Profitability
EBITDA Margin (%)	-	-2,218.75%	-	-	-	-	-	-990.4%
EBIT Margin (%)	-	-3,736.11%	-	-	-	-	-	-1,423.43%
EBT Margin (%)	-	-3,729.17%	-	-	-	-	-	-1,356.81%
Net margin (%)	-	-3,729.17%	-	-	-	-	-	-1,308.48%
FCF margin (%)	-	-2,217.82%	-	-	-	-	-	-1,048.54%
FCF / Net Income (%)	-	59.47%	67%	100.17%	88.28%	95.35%	91.65%	80.13%
Profitability
ROA	-	-	-	-	-	-	-	-
ROE	-	-73.59%	-79.15%	-76.36%	-45.91%	-44.7%	-78.6%	-53.2%
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	-	15.62%	-	-	-	-	-	84.48%
CAPEX / EBITDA (%)	-	-0.7%	-0.23%	-0.3%	-0.03%	-0.36%	-4.3%	-8.53%
CAPEX / FCF (%)	-	-0.7%	-0.23%	-0.3%	-0.03%	-0.45%	-4.39%	-8.06%
Items per share
Cash flow per share ¹	-	-7.23	-10.27	-9.72	-8.303	-5.1	-4.64	-3.31
Change	-	-	-42.02%	5.33%	14.58%	38.58%	9.02%	28.66%
Dividend per Share ¹	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Book Value Per Share ¹	-	32.72	17.3	9.88	35.18	10.47	5.62	14.71
Change	-	-	-47.14%	-42.88%	256.12%	-70.24%	-46.32%	161.74%
EPS ¹	-	-12.16	-15.2	-9.88	-9.5	-3.798	-3.554	-4.104
Change	-	-	-25%	35%	3.85%	60.02%	6.43%	-15.48%
Nbr of stocks (in thousands)	-	4,126	4,565	5,183	20,005	21,036	21,036	21,036
Announcement Date	-	6/28/21	6/22/22	6/27/23	6/26/24	-	-	-